Kaifeng Darui Pharmaceutical Co., Ltd.

博文

Year-Round Parasite Control for Grazing Cattle: A 5-Time Deworming Schedule

Parasitic infections pose a significant threat to the health and productivity of grazing cattle, especially in rural settings where preventive measures are often overlooked. Regular deworming is essential to combat internal and external parasites that can lead to weight loss, anemia, poor growth, and even death. This article outlines a science-backed, five-time deworming schedule tailored for rural free-range cattle, ensuring optimal health throughout the year. Why Deworming Matters Cattle, particularly those raised in open pastures, are vulnerable to a range of parasites: Internal parasites (e.g., roundworms, liver flukes) damage the digestive system and reduce nutrient absorption. External parasites (e.g., ticks, lice, mites) cause skin irritation, blood loss, and transmit diseases. Bloodborne parasites like Babesia (causing babesiosis or “cattle fever”) can be fatal if untreated. Untreated infestations weaken immunity, stunt growth, and lower meat/milk pro...

Enhancing Pork Quality and Carcass Composition in Growing-Finishing Pigs Through Nutritional Supplementation: A Deep Dive into Creatine Monohydrate and Its Synergistic Combinations

The global demand for high-quality pork continues to rise, driven by consumer preferences for leaner meat with improved tenderness, juiciness, and sensory attributes. In response, the swine industry has sought innovative nutritional strategies to optimize carcass composition and meat quality. Among these, creatine monohydrate (CMH) has emerged as a promising feed additive due to its role in energy metabolism and muscle physiology. This blog explores a groundbreaking study investigating the effects of CMH alone and in combination with other bioactive compounds—α-lipoic acid (ALA), taurine (Tau), and L-malic acid (LMA)—on growth performance, carcass traits, and meat quality in growing-finishing pigs. Background and Significance The Role of Creatine in Muscle Physiology Creatine is a naturally occurring compound synthesized in the liver, kidneys, and pancreas from arginine, glycine, and methionine. It serves as a critical energy reservoir in muscle cells, facilitating the rap...

The Turbulent Journey of “Female Viagra”: A Reflection on Science, Society, and Capital

In the world of pharmaceuticals, the story of flibanserin, commonly known as “female Viagra” or Addyi, is a fascinating yet controversial one. It serves as a microcosm of the intricate interplay between scientific research, societal values, and corporate interests. Flibanserin’s origins can be traced back to the 1990s when Boehringer Ingelheim, a German pharmaceutical giant, developed it as an antidepressant. However, clinical trials showed disappointing results in treating depression, and the drug seemed destined for the scrapheap. But then, an unexpected discovery was made. Female patients reported an increase in their sexual desire while taking the medication. With the growing recognition of Hypoactive Sexual Desire Disorder (HSDD) among women and the limited effectiveness of traditional treatments, Boehringer Ingelheim saw a new opportunity and shifted its focus. The drug’s mechanism of action is unique, with its “dual receptor modulation” property, acting on 5-HT1A and 5-HT2A rece...

Kaifeng Darui Pharmaceutical Co., Ltd.

Dedicated to high-end pharmaceutical raw materials, food additives, and intermediates.

About Us

Kaifeng Darui Pharmaceutical Co., Ltd., established on June 19, 2020, with a registered capital of 27 million RMB, is a high-tech enterprise located in the Kaifeng Fine Chemical Industrial Park. We focus on the R&D, production, and sales of high-end pharmaceutical raw materials, food additives, and intermediates.

We are a professional GMP-certified manufacturer of veterinary non-sterile APIs, strictly adhering to veterinary GMP requirements in design and construction. Our facility boasts a clean production environment and a rational layout.

We uphold the concept of green development, emphasizing talent and team building to achieve sustainable and healthy growth.

Financial Highlights:

2023 Total Output Value: 44 million RMB, Tax Contribution: 1.45 million RMB.
2024 Total Output Value: Over 60 million RMB, Tax Contribution: 2 million RMB.

Company Philosophy: "Survive by quality, root in talent; develop by technology, benefit from management." We persistently pursue excellent quality and a perfect brand and corporate image.

Research & Development

Since our inception, we established a dedicated technical team for R&D and technology introduction. Currently, we employ over 100 staff, with more than 20 R&D professionals (over 20% of workforce). Over 70% hold college degrees or higher, including 2 senior engineers, 2 associate professors, 1 lecturer, and 4 intermediate engineers.

We possess an independent R&D center (320 sq meters) with professional chemical laboratories and dedicated testing/analysis units. Our equipment includes HPLC, GC, UV-Vis Spectrophotometers, analytical balances, moisture analyzers, etc.

We collaborate closely with domestic universities and research institutions like Henan Academy of Sciences Chemical Research Institute Co., Ltd., Pingdingshan University, and Xinxiang Medical University to foster industry-university-research cooperation.

Facilities

Our plant is designed and built according to "Veterinary Drug Manufacturing Quality Management Standards".

Non-sterile API workshop (700 sq meters) with synthesis and refining/drying/packaging sections.
Two production lines with separate air purification systems; clean areas meet Class D standards.
Standardized production workshops, distillation equipment, 150 t/d wastewater treatment facility, and RCO exhaust gas treatment unit.
Water production equipment and air conditioning/purification systems.
Warehousing: Raw/auxiliary material, finished product, packaging material, and special management finished product warehouses.

Qualifications & Honors

High-tech Enterprise Certification (2023).
Henan Province Innovative Small and Medium-sized Enterprise (Dec 2022).
Kaifeng City Alkane Bromination Product Engineering Technology Research Center (2023).
Loving Charity Enterprise Title (Jan 2023).
Kaifeng Pharmaceutical Industry Association Council Member (Since 2021), Chairman Yang Xiaoke appointed as Council Director (Jan 2024).
Veterinary Drug Production License and 18 API GMP Certificates from Henan Provincial Department of Agriculture and Rural Affairs (Nov 2024).

Intellectual Property

We emphasize technological innovation and transformation. As of the report date, we hold 12 utility model patents, with 4 applications pending. These patents enhance our independent innovation capabilities and promote the transformation of scientific achievements.

Products & Services / Cooperation

Focus Areas:

Fine Chemicals & APIs
Food Additives
Fine Chemical & Pharmaceutical Intermediates

Areas for Cooperation:

Development of new veterinary and pet APIs.
Development of new food additives.
Cooperation on key production technologies, development and application of fine chemicals and pharmaceutical intermediates.

Future Outlook & Industry Prospects

As a certified High-tech Enterprise, we aim to standardize R&D project management, enhance innovation, and follow the growth path of quality SMEs (Sci-tech SME, Innovative SME, "Specialized, Refined, Unique, New" SME, Sci-tech Little Giant).

Key Development Directions:

Leveraging alkane bromination technology, establishing a national-level R&D, demonstration, training, pilot testing, and cooperation base.
Strengthening high-value-added biomedical fine products based on existing antiviral and anthelmintic products through R&D and university collaborations.
Continuing focus on veterinary APIs, capitalizing on the growing pet market, expanding livestock farming needs, and increasing international competitiveness and export opportunities for Chinese veterinary APIs.

Three-Year Goal (Targeting 2025): Achieve 100 million RMB in production and sales value, increase R&D investment to 20 million RMB, develop 2-3 new products annually, and attain the "Specialized, Refined, Unique, New" enterprise status.